ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis
ACS Nano · 2023-12-26 · 17 (24) · 24696-24709
DOI: 10.1021/acsnano.3c04497 ↗At a glance
Journal article in ACS Nano, published online on 2023-12-05. Written by Ngoc Man Phan and 4 co-authors. Institution: School of Chemical Engineering, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea. Major MEDLINE topics: Multiple Sclerosis, Encephalomyelitis, Autoimmune, Experimental, Vaccines. Cited 30 times so far (Crossref); 58 references. Funded by: National Research Foundation of Korea, Korea Forest Service.
Abstract (original language)
Multiple sclerosis (MS) is a demyelinating autoimmune disease, in which the immune system attacks myelin. Although systemic immunosuppressive agents have been used to treat MS, long-term treatment with these drugs causes undesirable side effects such as altered glucose metabolism, insomnia, and hypertension. Herein, we propose a tolerogenic therapeutic vaccine to treat MS based on lignin nanoparticles (LNP) with intrinsic reactive oxygen species (ROS)-scavenging capacity derived from their phenolic moieties. The LNP loaded with autoantigens of MS allowed for inducing tolerogenic DCs with low-level expression of costimulatory molecules while presenting antigenic peptides. Intravenous injection of an LNP-based tolerogenic vaccine into an experimental autoimmune encephalomyelitis (EAE) model led to durable antigen-specific immune tolerance via inducing regulatory T cells (Tregs). Autoreactive T helper type 1 cells, T helper type 17 cells, and inflammatory antigen presentation cells (APCs) were suppressed in the central nervous system (CNS), ameliorating ongoing MS in early and late disease states. Additionally, the incorporation of dexamethasone into an LNP-based tolerogenic nanovaccine could further improve the recovery of EAE mice in the severe chronic stage. As lignin is the most abundant biomass and waste byproduct in the pulping industry, a lignin-based tolerogenic vaccine could be a novel, cost-effective, high-value vaccine platform with potent therapeutic efficiency in treating autoimmune diseases.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Chemical Engineering, Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.
- Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.
- Institute of Quantum Biophysics (IQB), Sungkyunkwan University, Suwon 16419, Republic of Korea.
ORCID profiles: Jaeyun Kim
Funding
- National Research Foundation of Korea
- Korea Forest Service
Cite
APA
Phan, N. M., Nguyen, T. L., Shin, H., Trinh, T. A., & Kim, J. (2023). ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis. ACS Nano, 17(24), 24696-24709. https://doi.org/10.1021/acsnano.3c04497
Vancouver
Phan NM, Nguyen TL, Shin H, Trinh TA, Kim J. ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis. ACS Nano. 2023;17(24):24696-24709. doi:10.1021/acsnano.3c04497
BibTeX
@article{Phan2023,
author = {Phan, Ngoc Man and Nguyen, Thanh Loc and Shin, Hyunsu and Trinh, Thuy An and Kim, Jaeyun},
title = {ROS-Scavenging Lignin-Based Tolerogenic Nanoparticle Vaccine for Treatment of Multiple Sclerosis},
journal = {ACS Nano},
year = {2023},
volume = {17},
number = {24},
pages = {24696--24709},
doi = {10.1021/acsnano.3c04497}
}
EUVIMED